Side-by-side comparison of AI visibility scores, market position, and capabilities
Vancouver BC premium athletic apparel (NASDAQ: LULU) ~$10.6B FY2024 revenue (+11%); women's yoga apparel leader, China +41%, US slowdown, men's 22%+ of revenue, competing with Nike and Alo Yoga.
lululemon athletica inc. is a Vancouver, British Columbia-based premium athletic apparel company — publicly traded on the NASDAQ (NASDAQ: LULU) as an S&P 500 Consumer Discretionary component — designing, making, and distributing technical athletic apparel (yoga, run, train, swim, golf) and lifestyle products for women (primary market), men (growing), and youth through 700+ company-owned retail stores and e-commerce at lululemon.com through approximately 36,000 employees. In fiscal year 2024 (ending February 2025), lululemon reported revenues of approximately $10.6 billion (+11% year-over-year), continuing its decade-long consistent double-digit revenue growth as the brand expanded internationally (China mainland growing 41% in FY2024, Rest of World growing 28%) while US growth slowed to low single digits as the premium yoga-adjacent apparel market reached maturation levels in core US metro markets. CEO Calvin McDonald's strategy has focused on building the international business (China, Europe, rest of world) to replicate the North American penetration that drove lululemon's exceptional 2014-2023 growth, while managing the Mirror connected fitness acquisition write-off ($500 million full goodwill impairment of the Mirror home fitness acquisition completed in June 2020 for $500 million — mirror business essentially wound down by 2023) and navigating US market saturation challenges that required product innovation investment to sustain domestic revenue growth. lululemon's core women's leggings business (Align, Wunder Under, Fast and Free pants — $100-148 price point, premium Luon and Everlux fabric technology) anchors the brand's category authority in performance athletic bottoms.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.